The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
Abstract
Background and Aims: Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection. Approach and Results: First, in patients with HCC, lenvatinib‐treated recurrent tumors had lower programmed death ligand 1 (PD‐L1) expression and regulatory T cell (Treg) infiltration compared with matched primary tumors. Consistently, in C57BL/6 wild‐type mice receiving anti–programmed cell death 1 (PD‐1) therapy, PD‐L1 expression and Treg infiltration in s.c. tumors were reduced when adding lenvatinib to the scheme. Mechanistically, on the one hand, FGF receptor 4 (FGFR4) was the most pivotal target in PD‐L1 down‐regulation by lenvatinib in vitro. Furthermore, lenvatinib reinforced the proteasomal degradation of PD‐L1 by blocking the FGFR4–glycogen synthase kinase 3β axis and rescued the sensitivity of interferon‐γ‐pretreated HCC cells to T‐cell killing by targeting FGFR4. On the other hand, the level of IL‐2 increased after anti‐PD‐1 treatment, but IL‐2‐mediated Treg differentiation was blocked by lenvatinib through targeting FGFR4 to restrain signal transducer and activator of transcription 5 (STAT5) phosphorylation. By regulating the variations in the number of Tregs and the tumor FGFR4 level in C57BL/6–forkhead box protein P3 (Foxp3DTR ) mice, we found that high levels of FGFR4 and Treg infiltration sensitized tumors to the combination treatment. Finally, high levels of FGFR4 and Foxp3 conferred immune tolerance but better response to the combined therapy in patient cohorts. Conclusions: Lenvatinib reduced tumor PD‐L1 level and Treg differentiation to improve anti‐PD‐1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor could serve as biomarkers for screening patients with HCC using lenvatinib plus anti‐PD‐1 combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327 · cited 1×
“2555 by classical cytotoxic CD8+ T cells (cytotoxic T lymphocytes) and associated with activation of antitumor immunity.(22,23) The results indicated that high FGFR4 expression or Treg infiltration in HCC was positively associated with the suppressive immune microenvironment in human HCC.”
BackgroundFinn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008
Signaling and Function of Interleukin-2 in T Lymphocytes
Ross, S. H., & Cantrell, D. A. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053352 · Cited by 975
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
Revisiting IL-2: Biology and therapeutic prospects
Abbas, A. K., Trotta, E., R. Simeonov, D., Marson, A., & Bluestone, J. A. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat1482 · Cited by 636
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., Matsuki, M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212513 · Cited by 460
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
Wu, J.-C., Huang, Y.-H., Chau, G.-Y., Su, C.-W., Lai, C.-R., Lee, P.-C., Huo, T.-I., Sheen, I.-J., Lee, S.-D., & Lui, W.-Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.009 · Cited by 435
Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Molecular therapies for HCC: Looking outside the box
Faivre, S., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 326
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
Lee, J. C., Mehdizadeh, S., Smith, J., Young, A., Mufazalov, I. A., Mowery, C. T., Daud, A., & Bluestone, J. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba0759 · Cited by 308
An early history of T cell-mediated cytotoxicity
Golstein, P., & Griffiths, G. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0009-3 · Cited by 284
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
Di Pilato, M., Kim, E. Y., Cadilha, B. L., Prüßmann, J. N., Nasrallah, M. N., Seruggia, D., Usmani, S. M., Misale, S., Zappulli, V., Carrizosa, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1215-2 · Cited by 210
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Li, H., Li, C.-W., Li, X., Ding, Q., Guo, L., Liu, S., Liu, C., Lai, C.-C., Hsu, J.-M., Dong, Q., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.252 · Cited by 182
Chiu, D. K.-C., Yuen, V. W.-H., Cheu, J. W.-S., Wei, L. L., Ting, V., Fehlings, M., Sumatoh, H., Nardin, A., Newell, E. W., Ng, I. O.-L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.074 · Cited by 170
Wang, Y., Dembowsky, K., Chevalier, É., Stüve, P., Korf‐Klingebiel, M., Lochner, M., Napp, L. C., Frank, H., Brinkmann, E., Kanwischer, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036053 · Cited by 130
Stross, L., Günther, J. C., Gasteiger, G., Asen, T., Graf, S., Aichler, M., Esposito, I., Busch, D. H., Knolle, P. A., Sparwasser, T. D., et al. (2012) · Hepatology · doi:10.1002/hep.25765 · Cited by 128
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Wu, R.-Y., Kong, P., Xia, L.-P., Huang, Y., Li, Z., Tang, Y.-Y., Chen, Y.-H., Li, X., Senthilkumar, R., Zhang, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2840 · Cited by 117
Shi, H., Liu, C., Tan, H., Li, Y., Nguyen, T.-L. M., Dhungana, Y., Guy, C. S., Vogel, P., Neale, G. A. M., Rankin, S. L., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.010 · Cited by 113
Zhao, N., Dang, H. T., Ma, L., Martin, S. P., Forgues, M., Ylaya, K., Hewitt, S. M., & Wang, X. W. (2020) · Hepatology · doi:10.1002/hep.31412 · Cited by 75
Zhang, Q., Zhang, Y., Chen, Y., Qian, J., Zhang, X., & Yu, K. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2548 · Cited by 70
IL‐10 producing type 2 innate lymphoid cells prolong islet allograft survival
Huang, Q., Ma, X., Wang, Y., Niu, Z., Wang, R., Yang, F., Wu, M., Liang, G., Rong, P., Wang, H., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012305 · Cited by 48
Zhang, Q., Liu, H., Wang, H., Lü, M., Miao, Y., Ding, J., Li, H., Gao, X., Sun, S., & Zheng, J. (2019) · PubMed · Cited by 44
Siah2 control of T-regulatory cells limits anti-tumor immunity
Scortegagna, M., Hockemeyer, K., Dolgalev, I., Poźniak, J., Rambow, F., Yan, L., Feng, Y., Tinoco, R., Otero, D. C., Zhang, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13826-7 · Cited by 31
EGF receptor activation by heterologous mechanisms
Carraway, K. L., & Sweeney, C. A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00076-4 · Cited by 22
Immune oncology in hepatocellular carcinoma—hype and hope
Wörns, M., & Galle, P. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31044-9 · Cited by 12
Cited by
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
CD8+ T cell exhaustion and cancer immunotherapy
Wang, Q., Qin, Y., & Li, B. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216043 · Cited by 155
Metadata
- Authors
- Yi, C., Chen, L., Lin, Z., Liu, L., Shao, W., Zhang, R., Lin, J., Zhang, J., Zhu, W., Jia, H., Qin, L., Lu, L., & Chen, J.
- Venue
- Hepatology
- Published
- 2021-08-25
- Volume
- 74
- Issue
- 5
- Pages
- 2544-2560
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3165017392
- Cited by
- 295
- References
- 41
- FWCI
- 17.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.